Boston Scientific Corp 8-K/A, filed Aug 2, 2021
Boston Scientific Corp (BSX)
8-K/A
2021-08-02
For: 2021-06-23
View Original
Added on
April 07, 2026
About this 8-K/A
Boston Scientific Corp filed this 8-K/A on August 2, 2021, reporting on events of June 23, 2021.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________________________________________
FORM 8-K/A
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
_____________________________________________________________________
Date of Report (Date of earliest event reported): August 2, 2021 (June 23, 2021 )
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||||||||
(Address of principal executive offices) (Zip Code)
(508 ) 683-4000
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(d) Election of Directors
On June 24, 2021, Boston Scientific Corporation (the “Company”) filed a Current Report on Form 8-K announcing the appointment of David S. Wichmann to the Company’s Board of Directors (the “Board”) on June 23, 2021. At the time of filing of that report, the Board had not determined the committee assignments for Mr. Wichmann. On July 28, 2021, the Board appointed Mr. Wichmann to serve as a member of the Audit Committee and the Risk Committee.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: | August 2, 2021 | BOSTON SCIENTIFIC CORPORATION | ||||||||||||
| By: | /s/ Vance R. Brown | |||||||||||||
| Vance R. Brown | ||||||||||||||
| Senior Vice President, General Counsel and Corporate Secretary | ||||||||||||||